Faculty profile

Jean-François Larouche

Back to faculty

Clinical ProfessorMédecineUniversité Laval

Jean-François Larouche

Clinical Professor

Médecine

Université Laval

Quebec City, Quebec, Canada

Supervision signals

Clinical faculty often co-supervise; many graduate programs need a core faculty member as the main supervisor.
24 publications in the last five years, latest in 2026.
Senior (last) author on 2 recent papers, a sign of leading a research group.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

1,380

Citations

Collaborators

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile

Search on Google Scholar

Search on ResearchGate

iDORCID OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their Université Laval profile.

Latest papers

IBCL-1506: Clinically Relevant Subgroup Analysis From the Randomized Phase 3 EPCORE FL-1 Trial: Treatment Effect of Epcoritamab With Lenalidomide and Rituximab in Relapsed/Refractory Follicular Lymphoma
Clinical Lymphoma Myeloma & Leukemia · 2026
First-Line Bruton's Tyrosine Kinase Inhibitor-Based Regimens for Mantle Cell Lymphoma.
Current oncology (Toronto, Ont.) · 2026
POSTER: IBCL-1506: Clinically Relevant Subgroup Analysis From the Randomized Phase 3 EPCORE FL-1 Trial: Treatment Effect of Epcoritamab With Lenalidomide and Rituximab in Relapsed/Refractory Follicular Lymphoma
Clinical Lymphoma Myeloma & Leukemia · 2026

All 56 publications

56 publications.

IBCL-1506: Clinically Relevant Subgroup Analysis From the Randomized Phase 3 EPCORE FL-1 Trial: Treatment Effect of Epcoritamab With Lenalidomide and Rituximab in Relapsed/Refractory Follicular Lymphoma

Lorenzo Falchi, Marcel Nijland, Kim Linton, Neta Goldschmidt, Benoît Tessoulin, David Belada, Shuo Ma, Jayr Schmidt Filho, Jianzhen Shen, Juan Miguel Bergua Burgués, Caterina Patti, Umberto Vitolo, Michal Kwiatek, Loic Ysebaert, Theodoros P. Vassilakopoulos, Alexander Egle, Jean-François Larouche, Gauri Sunkersett, Mark A. Rocco, Nabanita Mukherjee, Rastislav Moskal, Yukun Li, Brian Elliot, Franck Morschhauser

Clinical Lymphoma Myeloma & Leukemia2026

DOI: 10.1016/s2152-2650(26)02737-0

First-Line Bruton's Tyrosine Kinase Inhibitor-Based Regimens for Mantle Cell Lymphoma.

Puckrin R, Villa D, Fleury I, Larouche JF, Kuruvilla J

Current oncology (Toronto, Ont.)2026Open Access

DOI: 10.3390/curroncol33070426 PMID: 42505228

POSTER: IBCL-1506: Clinically Relevant Subgroup Analysis From the Randomized Phase 3 EPCORE FL-1 Trial: Treatment Effect of Epcoritamab With Lenalidomide and Rituximab in Relapsed/Refractory Follicular Lymphoma

Clinical Lymphoma Myeloma & Leukemia2026

DOI: 10.1016/s2152-2650(26)01215-2

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial

Lorenzo Falchi, Marcel Nijland, Huiqiang Huang, Kim Linton, John Francis Seymour, Rong Tao, Michał Tomasz Kwiatek, Abel Costa, Theodoros P. Vassilakopoulos, Richard Greil, Ana Jiménez Ubieto, Shane A. Gangatharan, Ohad Benjamini, Catherine Thieblemont, Alessandra Tucci, Anna Elinder-Camburn, Arpád Illés, Jan Novák, Miguel Arturo Pavlovsky, Andrew Bruce McDonald, Dok Hyun Yoon, Dai Maruyama, Gauri Sunkersett, Jian Mei, Nabanita Mukherjee, Feng Zhu, Abualbishr Alshreef, Elena Favaro, Franck Morschhauser, Panagiotis D. Tsirigotis, et al. (198 authors)

The Lancet202527 citationsOpen Access

DOI: 10.1016/s0140-6736(25)02360-8 PMID: 41371238

Analysis of peripheral neuropathy in the POLARIX study using clinician- and patient-reported outcomes

Marek Trněný, Laura Fogliatto, Faithlore Patrice Gardner, Ian W. Flinn, Jean-François Larouche, Corinne Haïoun, Miguel Ángel Canales, Hideki Goto, Roman Hájek, Gilles Salles, Avrita Singh, Mark Yan, Rucha Kothari, Gabriel Man, Deniz Goren Sahin, Jamie H. Hirata, Calvin Lee, H. Tilly, Christopher R. Flowers

Blood Advances20252 citationsOpen Access

DOI: 10.1182/bloodadvances.2024014695 PMID: 40088467

Efficacy and tolerability of bendamustine, rituximab and acalabutinib in elderly treatment naïve Waldenström's macroglobulinemia

Suleman A, Roos K, Jiang Y, Tomlinson G, Mangoff K, Klein G, Villa D, Macdonald D, Aljama M, Shafey M

Blood20251 citations

DOI: 10.1182/blood-2025-1814

54 | FIXED DURATION TREATMENT OF BENDAMUSTINE‐RITUXIMAB AND ACALABRUTINIB IN FRONTLINE WALDENSTROM’S MACROGLOBULINEMIA: DEEP MOLECULAR RESPONSES IN HIGH‐RISK PATIENT SUBSETS

Suleman A, Roos K, Mangoff K, Jiang Y, Klein G, Villa D, MacDonald D, Aljama M, Shafey M, Forward N

Hematological Oncology2025Open Access

DOI: 10.1002/hon.70093_54

Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma-outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisplatin (R-DICEP) versus R-GDP.

Stewart DA, Kuruvilla J, Lee D, Dudebout JJ, Chua N, Larouche JF, Baetz T, Shafey M, Abdel-Samad N, Robinson S, Fleury I, Fraser G, Skrabek P, Kukreti V, Kelly J, Hay AE, Shepherd LE, Chen BE, Crump M

British journal of haematology20245 citationsOpen Access

DOI: 10.1111/bjh.19555 PMID: 38802107

A randomized trial of ibrutinib and R-GDP prior to stem cell transplant in relapsed diffuse large B-cell lymphoma.

Kuruvilla J, Rushton C, Villa D, Aslam M, Prica A, Abdel Samad N, Doucet S, Dudebout J, Fleury I, Fraser G, Larouche JF, Shafey M, Skrabek P, Skamene T, Morin RD, Alcaide M, Ben-Neriah S, Lee D, Winch C, Shepherd LE, Scott DW, Crump M, Chen BE, Hay AE

British journal of haematology20243 citationsOpen Access

DOI: 10.1111/bjh.19764 PMID: 39267295

Indolent Lymphoma: Well Tolerated, Fixed Duration Treatment Involving Bendamustine, Rituximab and Acalabrutinib for Front-Line Waldenström's Macroglobulinaemia That Induce Deep Clinical Responses

Suleman A, Roos K, Mangoff K, Jiang Y, Klein G, McClure R, Forward NA, Shafey M, Nikonova A, Sebag M

Blood20242 citationsOpen Access

DOI: 10.1182/blood-2024-203317

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Jean-François Larouche

Research

Latest papers

IBCL-1506: Clinically Relevant Subgroup Analysis From the Randomized Phase 3 EPCORE FL-1 Trial: Treatment Effect of Epcoritamab With Lenalidomide and Rituximab in Relapsed/Refractory Follicular Lymphoma

First-Line Bruton's Tyrosine Kinase Inhibitor-Based Regimens for Mantle Cell Lymphoma.

POSTER: IBCL-1506: Clinically Relevant Subgroup Analysis From the Randomized Phase 3 EPCORE FL-1 Trial: Treatment Effect of Epcoritamab With Lenalidomide and Rituximab in Relapsed/Refractory Follicular Lymphoma

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial

Analysis of peripheral neuropathy in the POLARIX study using clinician- and patient-reported outcomes

Efficacy and tolerability of bendamustine, rituximab and acalabutinib in elderly treatment naïve Waldenström's macroglobulinemia

54 | FIXED DURATION TREATMENT OF BENDAMUSTINE‐RITUXIMAB AND ACALABRUTINIB IN FRONTLINE WALDENSTROM’S MACROGLOBULINEMIA: DEEP MOLECULAR RESPONSES IN HIGH‐RISK PATIENT SUBSETS

Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma-outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisplatin (R-DICEP) versus R-GDP.

A randomized trial of ibrutinib and R-GDP prior to stem cell transplant in relapsed diffuse large B-cell lymphoma.

Indolent Lymphoma: Well Tolerated, Fixed Duration Treatment Involving Bendamustine, Rituximab and Acalabrutinib for Front-Line Waldenström's Macroglobulinaemia That Induce Deep Clinical Responses

Frequent collaborators

Mona Shafey

Anil Nigam

John Kuruvilla

Éric Thorin

Mohammed Aljama

Annette Hay

David Scott

Michael Sebag

Pamela Skrabek

Nathalie Johnson

Graeme Fraser

Bingshu Chen

George Tomlinson

Natasha Kekre

Katherine Zukotynski

Sandra Cohen

Samantha Mayo

Matthew Cheung

Ryan Morin

Joseph Connors